FDA takes additional action to better understand safety of Essure, inform patients of potential risks

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA takes additional action to better understand safety of Essure, inform patients of potential risks

	February 2016 www.fda.gov/womens FDA takes additional action to better understand safety of Essure, inform patients of potential risks The U.S. Food and Drug Administration announced today actions to provide important information about the risks of using Essure and to help women and their doctors be better informed of the potential complications associated with implantable forms of sterilization. The FDA issued a new, mandatory clinical study for Essure to determine heightened risks for particular women. The FDA also intends to require changes to product labeling, including a boxed warning and a Patient Decision Checklist to help to ensure women receive and understand information regarding the benefits and risks of this type of device. The FDA has issued a draft guidance to provide the public an opportunity to comment on the proposed language to be included in these warnings. Read the Press Release Get Essure Information for Patients Read the Draft Guidance Please share this update with your network, members, constituents, and community. FDA Office of Women’s Health 10903 New Hampshire Avenue WO32 - Room 2333 Silver Spring, MD 20993-0002 301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)